{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:43:56Z","timestamp":1789533836980,"version":"build-2803163510"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Medical Research Council"},{"name":"NICHD","award":["HD 47177"],"award-info":[{"award-number":["HD 47177"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Protease inhibitors (PIs) are used as a first-line regimen in HIV-1-infected children. Here we investigated the phenotypic consequences of amino acid changes in Gag and protease on lopinavir (LPV) and ritonavir (RTV) susceptibility among pediatric patients failing PI therapy. The Gag-protease from isolates from 20 HIV-1 subtype C-infected pediatric patients failing an LPV and\/or RTV-based regimen was phenotyped using a nonreplicative<jats:italic>in vitro<\/jats:italic>assay. Changes in sensitivity to LPV and RTV relative to that of the matched baseline (pretherapy) sample were calculated. Gag and protease amino acid substitutions associated with PI failure were created in a reference clone by site-directed mutagenesis and assessed. Predicted phenotypes were determined using the Stanford drug resistance algorithm. Phenotypic resistance or reduced susceptibility to RTV and\/or LPV was observed in isolates from 10 (50%) patients, all of whom had been treated with RTV. In most cases, this was associated with protease resistance mutations, but substitutions at Gag cleavage and noncleavage sites were also detected. Gag amino acid substitutions were also found in isolates from three patients with reduced drug susceptibilities who had wild-type protease. Site-directed mutagenesis confirmed that some amino acid changes in Gag contributed to PI resistance but only in the presence of major protease resistance-associated substitutions. The isolates from all patients who received LPV exclusively were phenotypically susceptible. Baseline isolates from the 20 patients showed a large (47-fold) range in the 50% effective concentration of LPV, which accounted for most of the discordance seen between the experimentally determined and the predicted phenotypes. Overall, the inclusion of the<jats:italic>gag<\/jats:italic>gene and the use of matched baseline samples provided a more comprehensive assessment of the effect of PI-induced amino acid changes on PI resistance. The lack of phenotypic resistance to LPV supports the continued use of this drug in pediatric patients.<\/jats:p>","DOI":"10.1128\/aac.02682-15","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T04:44:41Z","timestamp":1454388281000},"page":"2248-2256","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy"],"prefix":"10.1128","volume":"60","author":[{"given":"Jennifer","family":"Giandhari","sequence":"first","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa"},{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan E.","family":"Basson","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa"},{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Department of Infection, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Parry","sequence":"additional","affiliation":[{"name":"Public Health England, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Cane","sequence":"additional","affiliation":[{"name":"Public Health England, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Coovadia","sequence":"additional","affiliation":[{"name":"Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Gertrude H. Sergievsky Center and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Hunt","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa"},{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Morris","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), Johannesburg, South Africa"},{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-63"},{"key":"e_1_3_3_3_2","volume-title":"The South African antiretroviral treatment guidelines","author":"Department of Health","year":"2013","unstructured":"Department of Health. 2013. The South African antiretroviral treatment guidelines. Department of Health, Pretoria, South Africa."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181642257"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-14-55"},{"key":"e_1_3_3_6_2","volume-title":"Global update on HIV treatment 2013: results, impact and opportunities","author":"WHO","year":"2013","unstructured":"WHO. 2013. Global update on HIV treatment 2013: results, impact and opportunities. WHO, Geneva, Switzerland."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800971"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000931"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000683"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283298f1f"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/v6104095"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032144"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/769627"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI71784"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182829092"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67399"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.08.007"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/v2112509"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000345"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283398216"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/135965350601100708","article-title":"Compensatory mutations at the HIV cleavage sites p7\/p1 and p1\/p6-gag in therapy-naive and therapy-experienced patients","volume":"11","author":"Verheyen J","year":"2006","unstructured":"Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, Fatkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R. 2006. Compensatory mutations at the HIV cleavage sites p7\/p1 and p1\/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 11:879\u2013887.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00628-09"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02356-08"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040036"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-8-70"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00266-14"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-014-0079-7"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.17.9422-9430.2003"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2014.0349"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1278"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0205"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/651454"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.055624-0"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.11.4964-4972.2001"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01228-10"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00689-08"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku296"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.15.7398-7406.2002"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181af829d"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2892"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02682-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02682-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:03:22Z","timestamp":1654214602000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02682-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1128\/AAC.02682-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02682-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"2015-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}